Latest Breaking News On - Registrational phase - Page 1 : comparemela.com

Bicycle Therapeutics plc: Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational

United statesUnited kingdomFrance generalGustave roussyYohann loriotJustin baderKevin leeDeborah elsonStephanie yaoExchange commissionInternational nonproprietary nameDrug administrationCorporate communicationsAmerican society for clinical oncologyBicycle toxinBicycle toxin conjugate

Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON (BUSINESS WIRE) May 23, 2024

United statesFrance generalUnited kingdomGustave roussyJustin baderKevin leeYohann loriotStephanie yaoDeborah elsonDrug administrationAmerican society for clinical oncologyCorporate communicationsInternational nonproprietary nameExchange commissionBicycle toxin conjugatesClinical oncology

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesDevelopment rd expensesExchange commissionArcus biosciences incExchange commission onAmerican association for cancer researchCompany annual report on formAdenosine axisAmerican associationCancer researchAnnual meetingFirst quarterCash equivalentsMarketable securitiesThird gilead agreementLong lived assets

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesUniversity of illinoisLisa ellenKenneth candidoRaza ahmedFerring pharmaceuticalsAmerican society of interventional pain physiciansKaken pharmaceutical co ltdSeikagaku corporationSeikagaku corporation japaneseJapanese ministry of healthLumbar disc herniationAmerican societyInterventional pain physiciansAnnual meeting

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical.

Terry rosenJohanna mercierDevelopment rd expensesExchange commission onExchange commissionCompany annual report on formArcus biosciences incArcus biosciencesChief commercial officerDomvanalimab zimberelimab milestonesSafety dataOverall survivalSynthetic control armFourth quarterFull yearCash equivalents